Viveve Medical Inc. (NASDAQ: VIVE) stock plunged to a 9-year low of $0.58 on Monday. Investors were concerned about the future of the medical technology company, which is focused on women’s intimate health, after a weak fourth-quarter earnings results. Traders believed the company could fall into bankruptcy if the worries persisted.
Is Vive a good stock to buy?
Is VIVEVE MEDICAL Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: VIVE) stock is to Strong Buy VIVE stock.
Will viveve Medical stock go up?
The Viveve Medical Inc stock price gained 0.47% on the last trading day (Friday, 8th Apr 2022), rising from $1.06 to $1.07....Predicted Opening Price for Viveve Medical Inc of Monday, April 11, 2022.Fair opening price April 11, 2022Current price$1.06$1.07 (Overvalued)
Is Oculus a publicly traded company?
Unfortunately right now, Oculus Rift isn't a publicly traded company. They remain very much a part of the Facebook family. If you want to invest in Oculus Rift you'll have to buy shares of Facebook for now.Jan 11, 2021
Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices
Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / January 13, 2022 / Viveve Medical, Inc.
Viveve to Participate in H.C. Wainwright BIOCONNECT Conference
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.
Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence
Major milestone achieved in Company's advance toward a new U. SUI indicationENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc.
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update
6M reported for Q3 * Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc.
Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update
ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.
Viveve Announces Issuance of New Device and Methods Patent in U.S
Issuance further expands and strengthens Company's intellectual property portfolioENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Australian Patent Office has issued Patent No.
